

## Recombinant Human sVEGFR-3/FLT-4

<b>Catalog No.</b>	CRF113-005	<b>Quantity:</b>	5 µg
	CRF113A		10 µg
	CRF113B		50 µg

**Description:** Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy-terminal 6X histidine-tag. The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774).

All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterized by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to haematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.

Molecular weight: 120 kDa

<b>Protein Accession No:</b>	P35916
<b>GenID:</b>	2324
<b>Source:</b>	Insect cells
<b>Formulation:</b>	Lyophilized
<b>Purity:</b>	> 90%, by SDS-PAGE and visualized by silver stain
<b>Endotoxin Level:</b>	< 0.1 ng per µg of sVEGFR-3
<b>Specific Activity:</b>	Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilized recombinant human sVEGFR-3/FLT-4 at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.

**NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**